Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02743598
Other study ID # 23284
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date September 2016
Est. completion date September 2018

Study information

Verified date July 2022
Source Temple University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test the effect of liraglutide on cognitive function in HIV-infected overweight or obese subjects with type 2 diabetes.


Description:

HIV, insulin resistance and type 2 diabetes mellitus (DM) are independently associated with cognitive impairment. Considering the synergistic effects of HIV and DM on cognition, these subjects are at increased risk of cognitive impairment. glucagon-like peptide 1 (GLP-1) receptors have wide tissue distribution including the central nervous system. The study hypothesis is that GLP-1 could potentially ameliorate the impairments in cognition in this population. This study will assess the impact of liraglutide on neurocognitive performance and peripheral inflammatory markers. It will also evaluate the effects of liraglutide on glycemic control and metabolic risk factors in HIV infected subjects with type 2 diabetes.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date September 2018
Est. primary completion date June 1, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - HIV controlled on therapy for at least 12 weeks - Viral load < 200 copies - BMI >27 to 45 - Diagnosis of DM type 2 with A1-C >7 to 15 - Participants must be willing to comply with all study related procedures Exclusion Criteria: - Personal or family history of pancreatitis - Medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2) - Gastroparesis - Allergy to liraglutide or any of the active ingredients in liraglutide or other GLP-1 analogue - Weight loss drugs other than metformin - Type 1 diabetes mellitus or diabetic ketoacidosis - Known major cognitive deficit dementia, history of head trauma with loss of consciousness >30 min, history of stroke, current central nervous system (CNS) disorder such as seizures or opportunistic CNS infection - Renal insufficiency defined as creatinine clearance < 60 mL/min - Active opportunistic infections - Pregnancy or breastfeeding - Unstable cardiovascular disease with hospitalization within 1 year for acute coronary syndrome - Decompensated heart failure - Substance abuse - Active alcohol or opioid substitution therapy - Serious or unstable medical or psychological conditions that would compromise the subject's safety for successful participation

Study Design


Intervention

Drug:
Liraglutide


Locations

Country Name City State
United States Cherie Vaz Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Temple University The Comprehensive NeuroAIDS Center (CNAC) at Temple University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neurocognitive performance- change in global cognitive scores on a standard neuropsychological profile 6 months
Primary Neurocognitive performance- change in domain averages on a standard neuropsychological profile 6 months
Secondary Change from baseline high sensitivity C-reactive protein 3 and 6 months
Secondary Change from baseline d-dimer 3 and 6 months
Secondary Change from baseline Interleukin 6 3 and 6 months
Secondary Change from baseline plasma soluble cluster of differentiation 14 (CD14) 3 and 6 months
Secondary Change from baseline BMI 3 and 6 months
Secondary Change from baseline weight 3 and 6 months
Secondary Change from baseline waist circumference 3 and 6 months
Secondary Change from baseline blood pressure 3 and 6 months
Secondary Change from baseline serum triglycerides 3 and 6 months
Secondary Change from baseline insulin resistance by homeostasis model assessment (HOMA-IR) in subjects not on insulin 3 and 6 months
Secondary Change from baseline liver enzymes aspartate aminotransferase and alanine aminotransferase 3 and 6 months
Secondary Change from baseline Hemoglobin A1c 3 and 6 months
Secondary Change from baseline fructosamine 3 and 6 months
Secondary Number of Adverse events 3 and 6 months
Secondary Number of subjects with Adverse events 3 and 6 months
Secondary Change from baseline serum LDL 3 and 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2